Literature DB >> 17657715

Inappropriate gold standard bias in cervical cancer screening studies.

Robert G Pretorius1, Yan-Ping Bao, Jerome L Belinson, Raoul J Burchette, Jennifer S Smith, You-Lin Qiao.   

Abstract

As acetic acid-aided visual inspection (VIA) and colposcopic-directed biopsy miss small >/=cervical intraepithelial neoplasia (CIN) 2, inflation of sensitivity of VIA may occur when colposcopic-directed biopsy is the gold standard for >/=CIN 2. To determine whether such inflation occurs, we reviewed 375 women with >/=CIN 2 from the Shanxi Province Cervical Cancer Screening Study II. These women had positive self or physician-collected tests for high-risk human papillomavirus or abnormal cervical cytology and had VIA followed by colposcopy with directed biopsy and endocervical curettage (ECC). If a cervical quadrant had no lesion, a random biopsy at the squamocolumnar junction within that quadrant was obtained. Sensitivity of colposcopic-directed biopsy was higher for >/=CIN 2 involving 3-4 cervical quadrants (81.3%) than for >/=CIN 2 involving 0-2 quadrants (49.0%, p < 0.001). Sensitivities of VIA, cytology of >/=ASC-US, >/=LSIL, and >/=HSIL were higher for >/=CIN 2 involving 3-4 quadrants than for >/=CIN 2 involving 0-2 quadrants. When a colposcopic-directed biopsy gold standard was compared with that of a 5-biopsy standard (which included >/=CIN 2 from colposcopic-directed biopsy, random biopsy, or ECC), the sensitivity for >/=CIN 2 of VIA was inflated by 20.0% (65.9% vs. 45.9%, p < 0.001). Sensitivities of other screening tests were not affected. Similar inflation of sensitivity of VIA was found with an endpoint of >/=CIN 3 (70.4% vs. 52.0%, p = 0.0013). Inflation of sensitivity of VIA depended upon agreement between colposcopic-directed biopsy and the screening tests as measured by kappa. Studies of VIA that used colposcopic-directed biopsy as the gold standard require reevaluation. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17657715     DOI: 10.1002/ijc.22991

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

Review 2.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Response to Pretorius and Belinson.

Authors:  Mark Schiffman; Liming Hu; Sameer Antani; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

4.  [Self-collection of test material. Supplement to cervical cancer screening].

Authors:  B R Mangold
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.

Authors:  Nicole G Campos; Philip E Castle; Thomas C Wright; Jane J Kim
Journal:  Int J Cancer       Date:  2015-05-21       Impact factor: 7.396

6.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

7.  Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya.

Authors:  Hugo De Vuyst; Michael H Chung; Iacopo Baussano; Nelly R Mugo; Vanessa Tenet; Folkert J van Kemenade; Farzana S Rana; Samah R Sakr; Chris J L M Meijer; Peter J F Snijders; Silvia Franceschi
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

8.  A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Authors:  Randy L Carter; Le Kang; Kathleen M Darcy; James Kauderer; Shu-Yuan Liao; William H Rodgers; Joan L Walker; Heather A Lankes; S Terence Dunn; Eric J Stanbridge
Journal:  Cancer Causes Control       Date:  2012-10-17       Impact factor: 2.506

9.  A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria.

Authors:  Kayode Olusegun Ajenifuja; Julia C Gage; Akinfolarin C Adepiti; Nicolas Wentzensen; Claire Eklund; Mary Reilly; Martha Hutchinson; Robert D Burk; Mark Schiffman
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

10.  Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in HIV-infected women in India.

Authors:  Vikrant V Sahasrabuddhe; Ramesh A Bhosale; Smita N Joshi; Anita N Kavatkar; Chandraprabha A Nagwanshi; Rohini S Kelkar; Cathy A Jenkins; Bryan E Shepherd; Seema Sahay; Arun R Risbud; Sten H Vermund; Sanjay M Mehendale
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.